FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients receiving BLINCYTO should be clinically monitored for signs and symptoms of infection and treated appropriately.
Croatian: Bolesnike liječene lijekom BLINCYTO treba klinički pratiti radi znakova i simptoma infekcije te odgovarajuće liječiti.
English: Complete remission (CR) CR a/CRh*
Croatian: Potpuna remisija (CR) CR a/CRh*
English: • The addition of water for injections to the powder for concentrate results in a total volume of 3.08 mL for a final BLINCYTO concentration of 12.5 mcg/mL.
Croatian: • Dodatak vode za injekcije prašku za koncentrat rezultira ukupnim volumenom od 3,08 ml za konačnu koncentraciju lijeka BLINCYTO od 12,5 µg/ml.
English: Infusion pump and intravenous tubing
Croatian: Infuzijska pumpa i intravenska cjevčica
English: 0/12, 0.0% (0.0, NE)
Croatian: 0/12 (0,0) (0,0, NP)
English: • chest pain or other pain
Croatian: • bol u prsnom košu ili druga bol
English: and a flip off cap.
Croatian: „flip-off“ poklopcem.
English: It is very important that the instructions for preparation and administration provided in this section are strictly followed to minimise medication errors (including underdose and overdose).
Croatian: Vrlo je važno da se strogo slijede upute za pripremu i primjenu navedene u ovom dijelu, kako bi se medikacijske pogreške svele na najmanju moguću mjeru (uključujući primjenu preniske ili previsoke doze).
English: If you have minimal residual disease acute lymphoblastic leukaemia, your dose of BLINCYTO will be 28 micrograms per day throughout the first cycle.
Croatian: Ako imate akutnu limfoblastičnu leukemiju s minimalnom rezidualnom bolešću, Vaša će doza lijeka BLINCYTO biti 28 mikrograma na dan tijekom prvog ciklusa.
English: 3 patients < 1 year of age refractory to prior treatment and without prior alloHSCT received one cycle of Blincyto at a dose of 5-15 µg/m2/day.
Croatian: 3 bolesnika u dobi < 1 godine refraktorna na prethodno liječenje i bez prethodnog aloHSCT-a primila su jedan ciklus lijeka Blincyto u dozi od 5-15 µg/m2/dan.
English: EFS time was calculated from the time of randomisation until the date of disease assessment indicating a relapse after achieving a CR/CRh*/CRi or death, whichever is earlier.
Croatian: d. Vrijeme preživljenja bez događaja računa se od trenutka randomizacije do datuma procjene bolesti ukazujući na relaps nakon postizanja CR/CRh*/CRi ili smrti, ovisno o tome što je nastupilo prije.
English: If you have or had neurological problems, it is recommended that the first 14 days of treatment will be given to you in a hospital or clinic.
Croatian: Ako imate ili ste imali neuroloških problema, preporučeno je da se liječenje provodi u bolnici ili klinici prvih 14 dana.
English: BLINCYTO is used to treat adults with acute lymphoblastic leukaemia.
Croatian: BLINCYTO se primjenjuje za liječenje odraslih osoba s akutnom limfoblastičnom leukemijom.
English: However high inter-patient variability was discerned (CV% up to 95.6%), and clearance values in renal impaired patients were essentially within the range observed in patients with normal renal function, no clinically meaningful impact of renal function on clinical outcomes is expected.
Croatian: Međutim, ustanovljena je visoka varijabilnost između bolesnika (CV% do 95,6%), te su vrijednosti klirensa u bolesnika s oštećenjem funkcije bubrega bile unutar raspona vrijednosti opaženih u bolesnika s normalnom funkcijom bubrega, te se ne očekuje značajan učinak funkcije bubrega na kliničke ishode.
English: BLINCYTO is used when acute lymphoblastic leukaemia has come back or has not responded to previous treatment (referred to as relapsed/refractory acute lymphoblastic leukaemia).
Croatian: BLINCYTO se koristi kada se akutna limfoblastična leukemija vratila ili nije bilo odgovora na prethodno liječenje (što se zove recidivirajuća ili refraktorna akutna limfoblastična leukemija).
English: Hyperbilirubinaemia includes blood bilirubin increased and hyperbilirubinaemia.
Croatian: Hiperbilirubinemija uključuje povišen bilirubin u krvi i hiperbilirubinemiju.
English: The estimated mean (SD) systemic clearance with continuous intravenous infusion in patients receiving blinatumomab in clinical studies was 2.92 (2.83) L/hour.
Croatian: Procijenjena srednja vrijednost (SD) sistemskog klirensa uz kontinuiranu intravensku infuziju u bolesnika u kojih se primjenjuje blinatumomab u kliničkim ispitivanjima bila je 2,92 (2,83) l/sat.
English: During the continuous intravenous infusion over 4 weeks, the pharmacodynamic response was characterised by T-cell activation and initial redistribution, rapid peripheral B-cell depletion, and transient cytokine elevation.
Croatian: Tijekom 4 tjedna kontinuirane intravenske infuzije, farmakodinamički odgovor bio je karakteriziran aktivacijom i početnom redistribucijom T limfocita, brzom deplecijom perifernih B limfocita i prolaznim povišenjem citokina.
English: Recommended daily dose by patient weight.
Croatian: Preporučena dnevna doza prema tjelesnoj težini bolesnika.
English: • if you develop chills or shivering, or feel warm; you should take your temperature as you may have a fever - these may be symptoms of an infection.
Croatian: • ako se u Vas pojavi zimica ili drhtanje, ili osjećaj topline; trebate si izmjeriti temperaturu jer možda imate vrućicu - to mogu biti simptomi infekcije.
English: Adverse reactions that were observed more frequently (≥ 10% difference) in the paediatric population compared to the adult population were anaemia, thrombocytopenia, leukopenia, pyrexia, infusion-related reactions, weight increase, and hypertension.
Croatian: Češće zamijećene nuspojave (s razlikom ≥ 10%) u pedijatrijskoj populaciji u usporedbi s odraslom populacijom bile su anemija, trombocitopenija, leukopenija, pireksija, reakcije povezane s infuzijom, povećanje tjelesne težine i hipertenzija.
English: No studies have been conducted to evaluate treatment-related effects on fertility.
Croatian: Nisu provedena ispitivanja za procjenu učinaka na plodnost povezanih s liječenjem.
English: These may include corticosteroids (e.g. dexamethasone).
Croatian: Ti lijekovi mogu uključivati kortikosteroide (npr. deksametazon).
English: Decreased immunoglobulins includes blood immunoglobulin G decreased, globulins decreased, hypogammaglobulinaemia, hypoglobulinaemia and immunoglobulins decreased.
Croatian: Sniženi imunoglobulini uključuju sniženi imunoglobulin G u krvi, snižene globuline, hipogamaglobulinemiju, hipoglobulinemiju i snižene imunoglobuline.
English: Pre-phase treatment for patients with high tumour burden
Croatian: Prethodno liječenje za bolesnike s velikim tumorskim opterećenjem
English: Patients who have achieved complete remission (CR/CRh*) after 2 treatment cycles may receive up to 3 additional cycles of BLINCYTO consolidation treatment, based on an individual benefits-risks assessment.
Croatian: U bolesnika koji su postigli potpunu remisiju (CR/CRh*, od eng. complete remission) nakon 2 ciklusa liječenja mogu se primijeniti do 3 dodatna ciklusa konsolidacijskog liječenja lijekom BLINCYTO, ovisno o procjeni omjera koristi i rizika za pojedinca.
English: Induction Cycle 1 Days 1-28
Croatian: Indukcijski ciklus 1 Dani 1 - 28
English: * Based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Croatian: * Prema NCI Zajedničkim kriterijima terminologije za nuspojave (CTCAE, od eng.
English: Elderly patients with MRD-positive ALL treated with BLINCYTO may have an increased risk of hypogammaglobulinaemia compared to younger patients.
Croatian: Stariji bolesnici s ALL-om s pozitivnim MRB-om liječeni lijekom BLINCYTO mogu imati povećani rizik od hipogamaglobulinemije u usporedbi s mlađim bolesnicima.
English: Other clinically relevant (as determined by treating physician) adverse reactions
Croatian: Druge klinički značajne (prema procjeni odgovornog liječnika) nuspojave
English: Blinatumomab has major influence on the ability to drive and use machines.
Croatian: Blinatumomab značajno utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Patients received BLINCYTO at a constant dose of 15 mcg/m2/day (equivalent to the recommended dosage of 28 mcg/day) for all treatment cycles.
Croatian: Bolesnici su primali lijek BLINCYTO u stalnoj dozi od 15 µg/m2/dan (ekvivalentno preporučenoj dozi od 28 µg/dan) za sve cikluse liječenja.
English: Patients greater than or equal to 45 kg receive a fixed-dose and for patients less than 45 kg, the dose is calculated using the patient's body surface area (BSA).
Croatian: Bolesnici tjelesne težine 45 kg ili veće primaju fiksnu dozu, a za bolesnike tjelesne težine manje od 45 kg doza se izračunava pomoću bolesnikove površine tijela (engl. body surface area, BSA).
English: The treated population (in the dose-finding, PK expansion, and efficacy parts) included 70 patients who received at least 1 infusion of BLINCYTO at the recommended dose; the mean number of treatment cycles was 1.5.
Croatian: Liječena populacija (u dijelovima vezanim uz određivanje doze, proširenje saznanja o PK parametrima i djelotvornost) uključivala je 70 bolesnika koji su primili najmanje 1 infuziju lijeka BLINCYTO u preporučenoj dozi; srednja vrijednost broja ciklusa liječenja bila je 1,5.
English: There is limited experience with BLINCYTO in patients ≥ 75 years of age.
Croatian: Iskustva s lijekom BLINCYTO u bolesnika u dobi od ≥ 75 godina su ograničena.
English: The patient alert card should contain:
Croatian: Kartica s upozorenjima za bolesnika treba sadržavati:
English: The adverse reactions in BLINCYTO-treated paediatric patients were similar in type to those seen in adult patients.
Croatian: Nuspojave u pedijatrijskih bolesnika liječenih lijekom BLINCYTO bile su slične onima viđenima u odraslih bolesnika.
English: • The entire volume of the reconstituted and diluted BLINCYTO will be more than the volume to be administered to the patient (240 mL).
Croatian: • Sveukupni volumen rekonstituiranog i razrijeđenog lijeka BLINCYTO biti će veći od volumena koji će se primijeniti bolesniku (240 ml).
English: • if you experience seizures, difficulty in speaking or slurred speech, confusion and disorientation, or loss of balance.
Croatian: • ako se u Vas jave napadaji, poteškoće u govoru ili nerazgovijetan govor, smetenost i dezorijentacija ili gubitak ravnoteže.
English: The primary endpoint was the complete remission/complete remission with partial haematological recovery (CR/CRh*) rate within 2 cycles of treatment with BLINCYTO.
Croatian: Primarni ishod bila je stopa potpune remisije/potpune remisije uz djelomičan hematološki oporavak (CR/CRh*, od eng. complete remission/complete remission with partial haematological recovery) unutar 2 ciklusa liječenja lijekom BLINCYTO.
English: a Complete MRD response was defined as the absence of detectable MRD confirmed in an assay with minimum sensitivity of 10-4 b One hundred thirteen patients (97.4%; 113/116) were included in the primary endpoint full analysis set
Croatian: a Potpuni MRB odgovor definiran je kao izostanak detektabinog MRB-a potvrđeno u testu s minimalnom osjetljivošću od 10b Stotinu trinaest bolesnika (97,4%, 113/116) uključeno je u potpuni skup podataka za analizu primarne mjere ishoda
English: It is very important that the instructions for preparation (including reconstitution and dilution) and administration are strictly followed to minimise medication errors (including underdose and overdose) (see section 4.2).
Croatian: Vrlo je važno strogo slijediti upute za pripremu (uključujući rekonstituciju i razrjeđivanje) i primjenu kako bi se medikacijske pogreške svele na najmanju moguću mjeru (uključujući primjenu preniske doze ili predoziranje) (vidjeti dio 4.2).
English: Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of BLINCYTO treatment, during treatment, and until recovery of B-lymphocytes to normal ranges following last treatment cycle.
Croatian: Cijepljenje živim virusnim cjepivima se ne preporučuje kroz najmanje 2 tjedna prije početka primjene lijeka BLINCYTO, tijekom liječenja i do oporavka B limfocita u raspone normalnih vrijednosti nakon posljednjeg ciklusa liječenja.
English: Refractory to salvage therapy Maximum of central/local bone marrow blasts - n (%)
Croatian: Refraktorni na spasonosnu terapiju Najveća vrijednost blasta u koštanoj srži centralno/lokalno - n (%)
English: Demographics and baseline characteristics in phase III study
Croatian: Tablica 1. Demografske i početne karakteristike u ispitivanju faze III
English: Patients who are receiving medicinal products that are CYP450 and transporter substrates with a narrow therapeutic index should be monitored for adverse effects (e.g. warfarin) or drug concentrations (e.g. cyclosporine) during this time.
Croatian: Bolesnike u kojih se primjenjuju lijekovi koji su supstrati CYP450 i transportera, s uskim terapijskim indeksom, treba tijekom tog vremena pratiti radi nuspojava (npr. varfarin) ili koncentracija lijeka (npr. ciklosporin).
English: The primary endpoint was the proportion of patients who achieved a complete MRD response within one cycle of BLINCYTO treatment.
Croatian: Primarna mjera ishoda bila je udio bolesnika koji su postigli potpuni MRB odgovor unutar jednog ciklusa liječenja lijekom BLINCYTO.
English: The nurse educational material should contain:
Croatian: Edukacijski materijali za medicinske sestre trebaju sadržavati:
English: In the elderly population (≥ 65 years of age) 11 of 25 patients (44.0%) achieved CR/CRh* within the first 2 treatment cycles (see section 4.8 for safety in elderly).
Croatian: U populaciji starijih osoba (u dobi od ≥ 65 godina) 11 od 25 (44,0%) bolesnika postiglo je CR/CRh* unutar prva 2 ciklusa liječenja (vidjeti dio 4.8 za informacije o sigurnosti u starijih osoba).
English: • 38.5 micrograms blinatumomab powder in a vial (type I glass) with a stopper (elastomeric rubber), seal (aluminium) and a flip off cap and
Croatian: • 38,5 mikrograma blinatumomaba u obliku praška u bočici (staklo tipa I) s čepom (elastomerna guma), zatvaračem (aluminij) i „flip-off“ poklopcem i
English: Patients were randomised 2:1 to receive BLINCYTO or 1 of 4 prespecified, investigator-selected, SOC backbone chemotherapy regimens.
Croatian: Bolesnici su randomizirani 2:1 za primanje lijeka BLINCYTO ili 1 od 4 prethodno specificirana, od ispitivača odabrana SOC temeljna kemoterapijska režima.
English: Median overall survival [95% CI]
Croatian: Medijan sveukupnog preživljenja [95% CI]
English: Infusion-related reactions is a composite term that includes the term infusion-related reaction and the following events occurring with the first 48 hours of infusion and event lasted <=2 days: pyrexia, cytokine release syndrome, hypotension, myalgia, acute kidney injury, hypertension, rash, tachypnea, swelling face, face oedema and rash erythematous.
Croatian: 17 Reakcije povezane s infuzijom složen su pojam koji uključuje reakciju povezanu s infuzijom i sljedeće događaje koji se javljaju u prvih 48 sati od infuzije u trajanju događaja od <=2 dana: pireksija, sindrom otpuštanja citokina, hipotenzija, mijalgija, akutna ozljeda bubrega, hipertenzija, osip, tahipneja, oticanje lica, edem lica i eritemski osip.
English: The recommended dose of BLINCYTO throughout each 4-week treatment cycle is 28 mcg/day.
Croatian: Preporučena doza lijeka BLINCYTO tijekom svakog ciklusa liječenja od 4 tjedna iznosi 28 µg/dan.
English: • Detailed description of the reconstitution and preparation procedures of BLINCYTO infusion solution for intravenous administration under aseptic conditions, using aseptic techniques.
Croatian: • Detaljan opis postupaka rekonstitucije i pripreme BLINCYTO otopine za infuziju za intravensku primjenu u aseptičkim uvjetima, primjenom aseptičkih tehnika.
English: Greater than or equal to 45 kg (fixed-dose)
Croatian: 45 kg ili veća (fiksna doza)
English: The active ingredient in BLINCYTO is blinatumomab.
Croatian: Djelatna tvar u lijeku BLINCYTO je blinatumomab.
English: Treatment with BLINCYTO can cause a decrease in the levels of certain white blood cells with or without fever (febrile neutropenia or neutropenia) or can lead to increased blood levels of potassium, uric acid, and phosphate and decreased blood levels of calcium (tumour lysis syndrome).
Croatian: Liječenje lijekom BLINCYTO može uzrokovati smanjenje razine određenih bijelih krvnih stanica s ili bez vrućice (febrilna neutropenija ili neutropenija) ili može dovesti do povećane razine kalija u krvi, mokraćne kiseline i fosfata u krvi, te smanjene razine kalcija u krvi (sindrom lize tumora).
English: Patients should be closely monitored for signs or symptoms of these events.
Croatian: Bolesnike treba pomno pratiti radi znakova i simptoma ovih događaja.
English: Talk to your doctor, pharmacist or nurse before using BLINCYTO if any of these apply to you.
Croatian: Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primijenite BLINCYTO ako se nešto od navedenog odnosi na Vas.
English: Overall
Croatian: Sveukupno
English: Gently swirl contents to avoid excess foaming.
Croatian: Nježno izmiješajte sadržaj kako bi se izbjeglo stvaranje pjene.
English: The choice of the infusion duration should be made by the treating physician considering the frequency of the infusion bag changes.
Croatian: Odluku o trajanju infuzije treba donijeti odgovorni liječnik, uzimajući u obzir učestalost promjene infuzijskih vrećica.
English: Speech disorder
Croatian: Poremećaj govora
English: During treatment, especially in the first few days after treatment start, you may experience a severe low white blood cell count (neutropenia), severe low white blood cell count with a fever (febrile neutropenia), elevated liver enzymes, or elevated uric acid.
Croatian: Tijekom liječenja, posebno u prvih nekoliko dana nakon početka liječenja, može doći do jako niskog broja bijelih krvnih stanica (neutropenija), jako niskog broja bijelih krvnih stanica uz vrućicu (febrilna neutropenija), povišenja jetrenih enzima ili povišenja mokraćne kiseline.
English: 5 Leukocytosis includes leukocytosis and white blood cell count increased.
Croatian: 5 Leukocitoza uključuje leukocitozu i povišen broj bijelih krvnih stanica.
English: RFS at 18 months not censored at HSCT or postBLINCYTO chemotherapy was 53% (44%, 62%).
Croatian: Preživljenje bez recidiva nakon 18 mjeseci bez cenzure kod HSCT-a ili kemoterapije nakon lijeka BLINCYTO, bilo je 53% (44%, 62%).
English: Do not use if the solution is cloudy or has precipitated.
Croatian: Nemojte primjenjivati ako je otopina mutna ili je došlo do taloženja.
English: Intravenous use after reconstitution and dilution.
Croatian: Intravenska primjena nakon rekonstitucije i razrjeđivanja.
English: Escalate to 28 mcg/day after 7 days if the toxicity does not recur.
Croatian: Povisite dozu na 28 µg/dan nakon 7 dana ako se toksičnost ponovno ne javi.
English: The safety and efficacy of BLINCYTO compared to standard of care (SOC) chemotherapy were evaluated in a randomised, open-label, multicentre, phase III study.
Croatian: Sigurnost i djelotvornost lijeka BLINCYTO u odnosu na standardno liječenje (SOC, od eng. standard of care) kemoterapijom procijenjene su u randomiziranom, otvorenom, multicentričnom ispitivanju faze III.
English: For patients with ≥ 50% leukaemic blasts in bone marrow or > 15,000/microlitre peripheral blood leukaemic blast counts treat with dexamethasone (not to exceed 24 mg/day).
Croatian: Bolesnike s ≥ 50% leukemičnih blasta u koštanoj srži ili s > 15 000 leukemičnih blasta po mikrolitru periferne krvi potrebno je liječiti deksametazonom (ne smije se prekoračiti 24 mg/dan).
English: The most serious adverse reactions that may occur during blinatumomab treatment include: infections (24.8%), neurologic events (13.8%), neutropenia/febrile neutropenia (10.1%), cytokine release syndrome (3.3%), and tumour lysis syndrome (0.7%).
Croatian: Najozbiljnije nuspojave do kojih može doći tijekom liječenja blinatumomabom uključuju: infekcije (24,8%), neurološke događaje (13,8%), neutropeniju/febrilnu neutropeniju (10,1%), sindrom otpuštanja citokina (3,3%) i sindrom lize tumora (0,7%).
English: 4.5 months (3.6, 9.0)
Croatian: 4,5 mjeseca (3,6, 9,0)
English: The metabolic pathway of blinatumomab has not been characterised.
Croatian: Metabolički put blinatumomaba nije još ustanovljen.
English: Treatment with BLINCYTO was associated with transient elevations in liver enzymes.
Croatian: Liječenje lijekom BLINCYTO bilo je povezano s prolaznim povišenjem jetrenih enzima.
English: For instructions on the handling and preparation of the medicinal product before administration, see section 6.6.
Croatian: Za upute o rukovanju i pripremi lijeka prije primjene, vidjeti dio 6.6.
English: Each BLINCYTO pack contains 1 vial of powder for concentrate for solution for infusion and 1 vial of solution (stabiliser):
Croatian: Svako pakiranje lijeka BLINCYTO sadrži 1 bočicu praška za koncentrat za otopinu za infuziju i 1 bočicu otopine (stabilizatora):
English: Table 7 provides instructions for patients weighing greater than or equal to 45 kg, whereas table 8 and table 9 provide instructions for patients weighing less than 45 kg.
Croatian: Tablica 7 daje upute za bolesnike tjelesne težine 45 kg ili veće, dok tablica 8 i tablica 9 daju upute za bolesnike tjelesne težine manje od 45 kg.
English: Store and transport refrigerated (2°C - 8°C).
Croatian: Čuvati i prevoziti u hladnjaku (2°C - 8°C).
English: Grade 3 (CTCAE version 4.0) or higher (severe or life-threatening) neurologic events following initiation of blinatumomab administration included encephalopathy, seizures, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.
Croatian: Neurološki događaji 3. (CTCAE verzija 4.0) ili višeg (teški ili po život opasni) stupnja nakon započinjanja primjene blinatumomaba uključivali su encefalopatiju, napadaje, poremećaje govora, poremećaje svijesti, konfuziju i dezorijentaciju te poremećaje koordinacije i ravnoteže.
English: • difficulty in speaking
Croatian: • otežan govor.
English: Tell your doctor, pharmacist or nurse immediately if you became pregnant whilst receiving BLINCYTO.
Croatian: Odmah obavijestite svog liječnika, ljekarnika ili medicinsku sestru ako zatrudnite dok se liječite lijekom BLINCYTO.
English: To coat the infusion bag, using a syringe, aseptically transfer 5.5 mL of the solution (stabiliser) to the infusion bag.
Croatian: Za oblaganje infuzijske vrećice, koristeći štrcaljku aseptički prenesite 5,5 ml otopine (stabilizatora) u infuzijsku vrećicu.
English: The starting volume (270 mL) is more than the volume administered to the patient (240 mL) to account for the priming of the intravenous tubing and to ensure that the patient will receive the full dose of BLINCYTO.
Croatian: Početni volumen (270 ml) veći je od volumena primijenjenog bolesniku (240 ml) zbog uračunatog volumena potrebnog za pripremu intravenske cjevčice i kako bi se osiguralo da će bolesnik primiti punu dozu lijeka BLINCYTO.
English: Complete MRD response a, n/N (%), [95% CI]
Croatian: Potpuni MRB odgovor a, n/N (%), [95% CI]
English: Infusion reactions may be clinically indistinguishable from manifestations of CRS (see section 4.8).
Croatian: Reakcije povezane s infuzijom ne moraju se klinički razlikovati od manifestacija CRS-a (vidjeti dio 4.8).
English: In the dose-finding part of the study, doses of up to 30 mcg/m 2/day were evaluated.
Croatian: U dijelu ispitivanja za određivanje doze, procijenjene su doze do 30 µg/m 2/dan.
English: Patients with low tumour burden (< 50%) responded best to BLINCYTO treatment with CR/CRh* rate of 72.9% (CI 59.7 - 83.6).
Croatian: Bolesnici s niskim tumorskim opterećenjem (< 50%) najbolje su odgovorili na liječenje lijekom BLINCYTO uz stopu CR/CRh* od 72,9% (CI 59,7 - 83,6).
English: However patients have been treated with blinatumomab in clinical studies after clearance of CSF blasts with CNS directed therapy (such as intrathecal chemotherapy).
Croatian: Međutim, bolesnici su u kliničkim ispitivanjima liječeni blinatumomabom nakon klirensa blasta iz CST-a putem terapije usmjerene na SŽS (poput intratekalne kemoterapije).
English: Infusion-related reactions a
Croatian: Reakcije povezane s infuzijom a